Ampersand Biomedicines (Series B)
Funding Details
Awarder
Inbox
Date Award
March 19, 2025
Vertical
Pharmaceuticals and Biotechnology
Funding URL
View Funding Page
Funding Amount
$65,000,000
Company Info
Founding Year
2021
Traction
Two lead programs in immuno-inflammation and immuno-oncology planned to enter IND-enabling studies in 2025. Second discovery partnership in obesity initiated.
Organizations Involved
Eli Lilly & Company, Pfizer
Founders
Flagship Pioneering
Market
Biologics
Location
Boston, Massachusetts, USA
Coinvestors
Flagship Pioneering, Eli Lilly & Company
Company Description

Ampersand Biomedicines is a multi-product platform that develops programmable medicines that target disease sites precisely.

Links
WebsiteCrunchbaseLinkedInTwitter
Back to HomeBack to Pharmaceuticals and Biotechnology DealsView Funding Announcement